Pharmaceutical Salts of Carvedilol: Polymorphism and Physicochemical Properties.

AAPS PharmSciTech

Dexa Laboratories of Biomolecular Sciences (DLBS), PT Dexa Medica, Industri Selatan V, Block PP No. 7, Jababeka Industrial Estate II, Cikarang, 17550, West Java, Indonesia.

Published: May 2017

We report novel pharmaceutical salts of an anti-hypertensive drug carvedilol (CVD) with pharmaceutically acceptable salt formers, including oxalic acid (OXA), fumaric acid (FUMA), benzoic acid (BZA), and mandelic acid (MDA) via conventional solvent evaporation technique. The pKa difference between CVD and selected acids was greater than 3, thus suggesting salt formation. Two polymorphic forms of CVD/MDA salts and one p-Dioxane solvate of CVD/FUMA salt were also reported in this paper. The salts were characterized by powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), and scanning electron microscopy (SEM). Stability of the salts was assessed by storage at 40°C/75% RH for 1 month. All CVD salts exhibited higher solubility in phosphate buffer solution pH 6.8 compared to the parent drug CVD and showed good stability in accelerated ICH conditions at 40°C/75% RH for 1 month. CVD/FUMA salt showed the highest solubility (1.78 times). Based on thermal analysis and slurry experiment, it was found that CVD/MDA polymorphs were related monotropically with Form 1 as the stable form. The results suggested that salt formation could be an alternative method to improve CVD solubility.

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12249-016-0616-xDOI Listing

Publication Analysis

Top Keywords

pharmaceutical salts
8
salt formation
8
cvd/fuma salt
8
40°c/75% 1 month
8
salts
5
cvd
5
salt
5
salts carvedilol
4
carvedilol polymorphism
4
polymorphism physicochemical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!